IMV INC (IMV)
(Delayed Data from NSDQ)
$4.40 USD
+0.70 (18.92%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.50 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
IMV [IMV]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: IMV
Industry: Medical - Drugs
Stepping to Sidelines Pending Strategic Review Visibility; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
2022 Results; MVP-S On Track to Deliver Clinical Milestones; Revising Target to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
First r/r DLBCL Look Makes Us Feel VITALIZEd; Reterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 5.00
Company: IMV
Industry: Medical - Drugs
First Look into Continued Clinical Development Plans for MVP-S; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
VITALIZE-d Data Teaser in r/r DLCBL; Data Presentation to Follow in 1Q23; Split-Adjusted Target to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
3Q22 Results; MVP-S On Track to Meet Important Milestones From VITALIZE and AVALON in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
2Q22 Results; Upcoming Data Readouts Set the Stage as Key Drivers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
AVALON Activates Site and Cash Balance Strengthened
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 5.00
Company: IMV
Industry: Medical - Drugs
MVP-S Confirms Safety and Targeted Clinical Activity in Ovarian Cancer at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
1Q22 Results; DPX-Pipeline on Track To Deliver Data on Multiple Indications in 2022 and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
AACR Results Add Confidence to DPX-Based Therapies in Bladder Cancer and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
R&D Day Highlights A Versatile Plug-and-Play Platform and Progress Across All Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
VITALIZE Doses First Patient With r/r DLBCL; Updates Set the Stage for 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 5.00
Company: IMV
Industry: Medical - Drugs
MVP-S Begins its Journey in HR+/HER2- Breast Cancer; Key Updates on Basket Trial and Beyond in December
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 5.00
Company: IMV
Industry: Medical - Drugs
3Q21 Results; DPX Platform On Track to Deliver Key Milestones in 2021 and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 12.50
Company: IMV
Industry: Medical - Drugs
Price: 25.00
Company: IMV
Industry: Medical - Drugs
1Q21 Results; Active Clinical Pipeline Signals Productive Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00
Company: IMV
Industry: Medical - Drugs
Maveropepimut-S Targets HR+/HER2- Breast Cancer; Phase 1b to Begin Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: IMV
Industry: Medical - Drugs
Maveropepimut-S in r/r DLBCL Moves Forward With Merck; Phase 2b Design Finalized to Begin in 2Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 10.00
Company: IMV
Industry: Medical - Drugs
2020 Results; Maveropepimut-S Going to Have Busy Year as Pipeline Also Expands
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Price: 25.00